Appreciation Partners Talk about Future Development Peak Pharmacy Celebrates 20th Anniversary
Release time:
2021-12-01
News from our newspaper This year is the 4th anniversary of the establishment of Jianfeng Pharmacy 20#. Taking advantage of the opportunities of the annual order meeting and the year-end business thank-you meeting, 11# June 26 , Jianfeng Pharmacy held a celebration meeting with the theme of "for 20 years, get together and start again " . More than 200 representatives of manufacturers and employees gathered together, review the unforgettable and wonderful development process of 20 years, and move forward hand in hand to the new goal in the future.
Deputy General Manager of the Group Company and General Manager of the Pharmaceutical Company Huang Jinlong, and Deputy Secretary of the Party Committee of the Pharmaceutical Company Dai Jinxiao attended the meeting. In his speech, Huang Jinlong thanked all sectors of the community for their concern and support for Jianfeng Pharmacy, and extended sincere greetings to all the staff who worked hard for Jianfeng Pharmacy. He said that drug retail has achieved steady growth under the dual influence of epidemic monitoring and prevention and the rise of online pharmacies. As the country continues to promote"Internet Medical " , online drug sales continue to develop. With the deepening of medical reform and the promotion of centralized procurement, prescription varieties will continue to grow in retail channels. Facing new opportunities and challenges, it is necessary to strengthen cooperation and common development. Jianfeng Pharmacy has been adhering to the management policy of "quality first, customer first, honest management, win-win cooperation " . It will continuously improve the quality and ability of service, strengthen the construction of pharmacist team, cooperate with production enterprises, introduce new varieties, actively explore new retail mode, and rely on the brand, capital and management advantages of the group company to continue to seek peer cooperation, continuously expand the scale, in the characteristic pharmacy, characteristic management efforts, stronger and bigger. Wu Weisheng, chairman of
Jianfeng Pharmacy, and Xiang Shunjiao, general manager of Jianfeng Pharmacy, also expressed their gratitude to their partners and old and new customers. They earnestly hope that all new and old friends will give Jianfeng Pharmacy greater support for mutual benefit and win-win results. They earnestly wish Jianfeng Pharmacy a prosperity, prosperity and further glory, and become a unique regional drug chain enterprise. At theconference, the best strategic cooperation award was awarded to partners such as Zhejiang Yingte, East China Medicine, Zhengda Tianqing and Amendment Liuwei, and the order meeting was held with the opportunity of representatives of many drug and medical device manufacturers. Representatives of various manufacturers and store managers displayed products and exchanged inquiries. The atmosphere was warm. (Reporter
Chen Shengmu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31